loading
Pasithea Therapeutics Corp stock is traded at $0.9002, with a volume of 35,250. It is down -3.22% in the last 24 hours and down -47.01% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
See More
Previous Close:
$0.91
Open:
$0.9288
24h Volume:
35,250
Relative Volume:
0.01
Market Cap:
$6.56M
Revenue:
-
Net Income/Loss:
$-16.28M
P/E Ratio:
-0.0647
EPS:
-13.91
Net Cash Flow:
$-13.75M
1W Performance:
-3.82%
1M Performance:
-47.01%
6M Performance:
-69.12%
1Y Performance:
-85.78%
1-Day Range:
Value
$0.8804
$0.9288
1-Week Range:
Value
$0.788
$0.95
52-Week Range:
Value
$0.788
$7.50

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name
Name
Pasithea Therapeutics Corp
Name
Phone
(702) 514-4174
Name
Address
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
2024-08-11
Name
Latest SEC Filings
Name
KTTA's Discussions on Twitter

Compare KTTA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KTTA
Pasithea Therapeutics Corp
0.8811 6.93M 0 -16.28M -13.75M -13.91
Biotechnology icon
ONC
Beigene Ltd Adr
243.72 25.57B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.38 111.79B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 39.90M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
594.18 65.28B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.56 6.31B 0 -153.72M -103.81M -2.00

Pasithea Therapeutics Corp Stock (KTTA) Latest News

pulisher
May 20, 2025

Pasithea’s PAS-004 shows promise in inflammatory disease study - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Reports Promising Preclinical Data for PAS-004 as a Novel MEK Inhibitor for Inflammatory Diseases - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Pasithea Therapeutics Announces Preclinical Data that Shows - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough: Novel IBD Drug Outperforms FDA-Approved Treatment in Targeting Key Inflammation Pathway - Stock Titan

May 20, 2025
pulisher
May 15, 2025

Neurofibromatosis Type 1 Market Set to Witness Significant Growth During the Study Period (2020–2034) Driven by Advances in Treatment | DelveInsight - GlobeNewswire Inc.

May 15, 2025
pulisher
May 15, 2025

Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Pasithea Therapeutics CEO sells shares worth $792 - Investing.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation Of Phase 1/1B Study Of Pas-004 In Adult Nf1 Patients And Activation Of First Clinical Trial Site - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Pasithea Therapeutics Announces Initiation of Phase 1/1B - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Phase 1/1b Trial: Pasithea's Once-Daily NF1 Drug Could Outperform Current Treatments - Stock Titan

May 14, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Raises $6.3 Million in Stock Offering - TipRanks

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Closes $5 Million Public Offering to Advance Development of PAS-004 for Neurofibromatosis and Cancer Indications - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics Announces Closing of $5 Million Public Offering - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

Pasithea Therapeutics 3.57M share Secondary priced at $1.40 - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated - Asianet Newsable

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing Of $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Stock Soars After Positive Data From Cancer Drug Trial: Retail’s Elated By Stocktwits - Investing.com India

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Prices $5 Million Public Offering - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics announces interim data from Phase 1 trial of PAS-004 - TipRanks

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics (KTTA) Skyrockets: Stock Soars Over 115% in Morning Trade - apnakal

May 06, 2025
pulisher
May 06, 2025

$5M Public Offering: Pasithea Therapeutics Advances MEK Inhibitor Drug for Rare Disease Treatment - Stock Titan

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results - Benzinga

May 06, 2025
pulisher
May 06, 2025

Pre-market Movers: KTTA, SXTC, GLMD, TCMD... - RTTNews

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 - Investing.com

May 06, 2025
pulisher
May 06, 2025

Pasithea reports promising data on cancer drug PAS-004 By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Promising Phase 1 Trial Results for PAS-004, Demonstrating Up to 91% pERK Inhibition and Tumor Volume Reduction in Advanced Cancer Patients - Nasdaq

May 06, 2025
pulisher
May 06, 2025

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Phase 1 Trial Reveals 91% Target Success: New Cancer Drug Shows Promise in Pancreatic Cancer Patient - Stock Titan

May 06, 2025
pulisher
May 01, 2025

Pasithea Therapeutics Files For Offering Up To 3.2 Mln Common Shares Together With Warrants, Says SEC Filing - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

AMD Stock Signals Strong Buy Ahead of Earnings - The Globe and Mail

May 01, 2025
pulisher
Apr 29, 2025

Pasithea completes enrollment in cohort 6 of Phase 1 trial of PAS-004 - TipRanks

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients - The Manila Times

Apr 29, 2025
pulisher
Apr 29, 2025

Pasithea's Cancer Drug Trial Hits Key Milestone: Latest Results from Advanced Treatment Study - Stock Titan

Apr 29, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics Announces Acceptance of Abstract for ASCO 2025 Presentation on PAS-004 Clinical Trial Data - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Pasithea Therapeutics to Present Updated Data from Ongoing - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

New PAS-004 Cancer Trial Data Shows Clinical Activity and Safety Profile | KTTA Stock News - Stock Titan

Apr 24, 2025
pulisher
Apr 15, 2025

Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 16.9% – Here’s What Happened - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing C - Asianet Newsable

Apr 14, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Pasithea Therapeutics Leads Healthcare Buzz Surge As Cancer Trial Clears Safety Hurdle, Moves To Next Dosing Cohort - MSN

Apr 11, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Gets Positive Safety Committee Recommendation for Advanced Cancer Drug Phase 1 Trial - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Dow Tumbles Over 800 Points; US Inflation Rate Falls In March - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

KTTA’s Unexpected Surge: Analysis of Recent Performance - timothysykes.com

Apr 10, 2025
pulisher
Apr 10, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics progresses with cancer drug trial - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation From Its Ongoing Phase 1 Clinical Trial Of Pas-004 In Advanced Cancer - MarketScreener

Apr 10, 2025

Pasithea Therapeutics Corp Stock (KTTA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Pasithea Therapeutics Corp Stock (KTTA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Marques Tiago
Chief Executive Officer
May 12 '25
Sale
0.82
960
792
40,001
$1.05
price down icon 8.70%
$30.28
price down icon 2.39%
$576.24
price down icon 0.61%
$287.50
price down icon 1.35%
$4.35
price up icon 1.64%
$73.93
price down icon 2.22%
Cap:     |  Volume (24h):